Arcellx Provides Second Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
-- The global Phase 3 trial, iMMagine-3, has been initiated by Kite -- -- U.S. FDA clears anito-cel IND application for myasthenia gravis, an autoimmune disease -- REDWOOD CITY, Calif., August 08, 2024 BUSINESS WIRE )--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2024. "We continue to make significant strides as we accelerate our business," said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. "We are thrilled about the momentum across our multiple myeloma program being developed in partnership with Kite. We believe anito-cel has the potential to be a best-in-class treatment option, and with the strength of our Kite partnership, we are well-positioned to change the treatment paradigm for multiple myeloma patients. We look forwar
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma [Seeking Alpha]Seeking Alpha
- Arcellx, Inc. (NASDAQ: ACLX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.MarketBeat
- Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
ACLX
Earnings
- 8/8/24 - Beat
ACLX
Sec Filings
- 9/17/24 - Form 4
- 9/17/24 - Form 144
- 9/12/24 - Form 4
- ACLX's page on the SEC website